

Pharmacy Notice

Magellan Medicaid Administration (MMA)

Louisiana Medicaid Single Managed Care Organization

(MCO) Pharmacy Benefits Manager (PBM)

GLP-1s Maximum Dose Limitations

September 3, 2024

The Louisiana Medicaid Preferred Drug List (PDL) has several point of sale (POS) safety edits on Glucagon-like peptide-1 (GLP-1) agonists, including a maximum dose (MD) edit. Currently, if a pharmacy claim submitted hits one of these edits, it will reject and allow for the pharmacist to override at POS if the dosage is verified as appropriate with the prescriber.

Link to access the PDL's GLP-1 POS document:

[POS.Diabetes.Hypoglycemics.Incretin.Mimetics.Enhancers.02062024.AprDUR.pdf \(la.gov\)](#)

Effective September 5, 2024, GLP-1s maximum dose can no longer be overridden at POS. If a maximum dose override is needed, the prescriber must complete a prior authorization justifying the need for prescribing a dose outside of these limits.

If you have any questions or concerns, please call Magellan at 1-800-424-1664.

Thank you,

Magellan Medicaid Administration

BIN#	025986
Processor Control #	1214172240
Group	LAMCOPBM